Некоторые аспекты терапии нейродегенеративных деменций
https://doi.org/10.21518/2079-701X-2014-10-36-41
Аннотация
Настоящая статья посвящена лечению нейродегенеративных деменций. Подробно рассмотрены вопросы эффективности ингибиторов ацетилхолинэстеразы, препаратов других фармакотерапевтических групп, а также комбинированной терапии с помощью ингибиторов ацетилхолинэстеразы и холина альфосцерата.
Об авторах
И. С. Преображенская
Клиника нервных болезней им. А.Я. Кожевникова, Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
Россия
Д. О. Громова
Клиника нервных болезней им. А.Я. Кожевникова, Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
Россия
Список литературы
1. Дамулин И.В. Болезнь Альцгеймера и сосудистая деменция. М., 2002.
2. Преображенская И.С. Экселон в терапии нейродегенеративных деменций. Неврологический журнал, 2006, 11, 1: 42-47.
3. Преображенская И.С. Когнитивные нарушения - выраженность, клинические проявления, диагностика, лечение. ДокторРу. 2013. 5 (83): 2-7.
4. Amenta F, Tayebati SK, Vitali D, Di Tullio MA. Association with the cholinergic precursor choline alphoscerate and the cho-linesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission. Mech Ageing Dev 2006. 127: 173-179.
5. Amenta F et al. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.J.NeurolSci. 2012. 15. 322. 1-2. 96-101.
6. Amenta F et al. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission. Mech Ageing Dev 2006. 127 (2). 173-9.
7. Arendt T, Bruckner MK, Lange M et al. Changes in acetylcholinesterase and, butyrilcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem Int. 1992. 21. 381-396.
8. Brodaty H, Sachdev PS. Drugs for the prevention and treatment of Alzheimer's disease. Med.J. Aust. 1997. 167. 8. 447-449.
9. Bullock R. New drugs for Alzheimer's disease and other dementias. Br.J. Psychiatry. 2002. 180. 135-139.
10. Cummings J, Lefevre G, Small G et al. Pharmacokinetic rationale for the rivasigmine patch. 2007. 69. 10-13.
11. Corey-Bloom J., Anand R., Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998. 1. 55-65.
12. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. ClinTher. 2003. 25: 1. 178-193.
13. Doggrell SA, Evans S. Treatment of dementia with neurotransmission modulation. Expert OpinInvestig Drugs 2003. 12. 1633-54.
14. Doraiswamy M, Anand R, Hartman R. Long-term cognitive effects in Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neurppsychopharmacol Biol Psychiatry. 2002. 26. 705-712.
15. Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer's disease. Lancet Neurology 2004, 3: 246-8.
16. Francis LS, Laplanche R. Absorbtion, metabolism and disposition of [14C] SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration. Pharmaceutical Research. 1998. 15. 10. 1614-1620.
17. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol Neurosurg Psychiat. 1999. 66. 137-147.
18. Galasko D. New approaches to diagnose and treat Alzheimer's disease: a glimpse of the future. Clin. Geriatr. Med. 2001. 17. 2. 393-410.
19. Lulu Xie et al. Sleep drives metabolite clearance from the adult brain. Science 2013. 342, 373.
20. Oertel W, Ross JS, Eggert K et al. Rationale for transdermal drug administration in Alzheimer's disease. Neurology. 2007. 69. 4-9.
21. Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. MechAgeingDev 2001. 122. 2041-55.
22. Small BJ, Fratiglioni L, Vitanen M et al. Vellas B et al. Research and practice in Alzheimer's disease. Paris: Serdi Publisher, 2001: 29-34.
23. Scapicchio PL. Int.J. Neurosci., 2013, 123 (7): 444.
24. Vellas B, Messina J, Hartman R et al. Multi-dimensionality of treatment benefits in Alzheimer's disease: investigating the correlation between activities of daily living and cognition in patients treated with rivastigmine. Research and practice in Alzheimer's disease. 5. Serdi Publishing (Paris), Springer Publishing Company (NY), 2001: 193-204.
Рецензия
Для цитирования:
Преображенская ИС, Громова ДО. Некоторые аспекты терапии нейродегенеративных деменций. Медицинский Совет. 2014;(10):36-41. https://doi.org/10.21518/2079-701X-2014-10-36-41
For citation:
Preobrazhenskaya IS, Gromova DO. Some aspects of treatment of neurodegenerative dementias. Meditsinskiy sovet = Medical Council. 2014;(10):36-41. (In Russ.) https://doi.org/10.21518/2079-701X-2014-10-36-41
Просмотров:
381
Послать статью по эл. почте 